CYLD and prostate cancer: Previous studies have disclosed several targets of miR‐301b‐3p, such as cytoplasmic polyadenylation element binding protein 3 in HGS‐OvCa,32 CYLD in breast cancer,18 leucine rich repeats and immunoglobulin like domains 1 in melanoma,23 early growth response gene 1 in bladder cancer,34 Bim in lung cancer,21 NR3C2 and TP63 in pancreatic cancer,15, 16 and NDRG2 in prostate cancer.29 Here, we identified VGLL4 as a novel target of miR‐301b‐3p in HCC.